secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115069
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Q3 net loss $12.7M; cash $26.9M; CT-0525 initial data expected Q1 2025
------------------------------------------------------------------------------

- Net loss of $12.7M in Q3 2024 vs $21.4M in Q3 2023; R&D expenses fell to $11.3M from $19.6M.
- Cash and equivalents $26.9M as of Sep 30, 2024, down from $40.4M at Jun 30; expected runway into Q3 2025.
- Phase 1 CT-0525 (HER2 CAR-Monocyte) initial data for Cohorts 1 and 2 expected Q1 2025; protocol amended for repeat dosing with pembrolizumab.
- Expanded Moderna collaboration to include two autoimmune targets; retains rights beyond those.
- Liver fibrosis development candidate nomination expected Q1 2025; preclinical data to be presented at AASLD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924115069/0001104659-24-115069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465924115069/tm2426977d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer